Clinical Trial Update: Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on IBI-323 plus bevacizumab and platinum chemotherapy in ALK-rearranged non-small cell lung cancer, with efficacy and biomarker co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• IBI-323
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN